Back to today’s briefing

Story perspectives

New HIV Treatment Achieves 96% Virologic Suppression Rate

3/17/2025

26 4

Summary

Story summary

At CROI 2025, Dr. Onyema Ogbuagu unveiled promising results from a Phase 2 study, revealing that a six-month treatment of lenacapavir, teropavimab, and zinlirvimab (LTZ) achieved an impressive 96% virologic suppression rate, rivaling daily oral therapies. This breakthrough not only showcases LTZ's effectiveness and safety but also paves the way for future research on its long-term benefits in HIV treatment.

1 of 1

Story summary

At CROI 2025, Dr. Onyema Ogbuagu unveiled promising results from a Phase 2 study, revealing that a six-month treatment of lenacapavir, teropavimab, and zinlirvimab (LTZ) achieved an impressive 96% virologic suppression rate, rivaling daily oral therapies. This breakthrough not only showcases LTZ's effectiveness and safety but also paves the way for future research on its long-term benefits in HIV treatment.